Can a new RSV vaccine keep adults out of the hospital? 690,000 join trial

NCT ID NCT06684743

Ongoing ⭐️ VACCINE ⭐️ Sponsor: Tor Biering-Sørensen Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This massive study is testing whether the Abrysvo RSV vaccine can prevent hospitalizations due to RSV in adults aged 18 and older. Half of the 690,000 participants will receive the vaccine, while the other half will not. Researchers will track how many in each group end up hospitalized for RSV-related illness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Abrysvo (RSV prefusion F protein-based vaccine)
What this could lead to: If successful, this could show that the Abrysvo vaccine effectively reduces RSV-related hospitalizations in a broad adult population, including younger adults.
What could go wrong: This is a pragmatic trial with no blinding, so results may be influenced by participant behavior. The vaccine's effectiveness may vary by age and health status, and rare side effects may only emerge in such a large study.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RSV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

respiratory system disorder respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RSV

Contacts and locations

Locations

Center for Translational Cardiology and Pragmatic Randomized Trials Department of Cardiology Copenhagen University Hospital - Herlev and Gentofte

Copenhagen, 2900, Denmark
Danske Lægers Vaccinations Service

Søborg, 2860, Denmark
General Public Health Directorate of Galician Health Service

Santiago de Compostela, A Coruña, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.